NCT01632228 2018-02-05
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
Clinical Trials
15 trialsNCT01418222 2017-05-30
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT01068977 2017-05-19
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT00854308 2017-03-31
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Genentech, Inc.
Phase 2 Completed
NCT02031731 2017-03-14
The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02031744 2017-03-14
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01186991 2017-01-20
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
Genentech, Inc.
Phase 2 Completed
NCT01456325 2016-11-02
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Genentech, Inc.
Phase 3 Completed
NCT01662869 2016-11-02
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01887886 2016-11-02
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Hoffmann-La Roche
Phase 3 Completed
NCT01897038 2016-11-02
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1 Completed
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01496742 2016-09-23
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT01519804 2016-09-02
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT01590719 2016-08-09
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
Hoffmann-La Roche
Phase 2 Completed